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Summary
Increased liver fat may be caused by insulin resistance and adipose tis-
sue inflammation or by the common I148M variant in PNPLA3 at 
rs738409, which lacks both of these features. We hypothesised that 
obesity/insulin resistance rather than liver fat increases circulating co-
agulation factor activities. We measured plasma prothrombin time (PT, 
Owren method), activated partial thromboplastin time (APTT), activ-
ities of several coagulation factors, VWF:RCo and fibrinogen, and 
D-dimer concentration in 92 subjects divided into groups based on in-
sulin sensitivity [insulin-resistant (‘IR’) versus insulin-sensitive (‘IS’)] 
and PNPLA3 genotype (PNPLA3148MM/MI vs PNPLA3148II). Liver fat con-
tent (1H-MRS) was similarly increased in ‘IR’ (13 ± 1 %) and 
PNPLA3148MM/MI (12 ± 2 %) as compared to ‘IS’ (6 ± 1 %, p<0.05) and 
PNPLA3148II (8 ± 1 %, p<0.05), respectively. FVIII, FIX, FXIII, fibrinogen 
and VWF:RCo activities were increased, and PT and APTT shortened in 
‘IR’ versus ‘IS’, in contrast to these factors being similar between 
PNPLA3148MM/MI and PNPLA3148II groups. In subjects undergoing a liver 
biopsy and entirely lacking the I148M variant, insulin-resistant sub-
jects had higher hepatic expression of F8, F9 and FGG than equally 
obese insulin-sensitive subjects. Expression of pro-inflammatory genes 
in adipose tissue correlated positively with PT (% of normal), circu-
lating FVIII, FIX, FXI, VWR:RCo and fibrinogen, and expression of anti-
inflammatory genes negatively with PT (%), FIX and fibrinogen. We 
conclude that obesity/insulin resistance rather than an increase in liver 
fat is associated with a procoagulant plasma profile. This reflects adi-
pose tissue inflammation and increased hepatic production of coagu-
lation factors and their susceptibility for activation.
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Introduction
Recent studies have shown that non-alcoholic fatty liver disease 
(NAFLD) is heterogeneous (1). Insulin resistance, obesity and sys-
temic low-grade inflammation characterise ‘Metabolic NAFLD’ 
and predispose to type 2 diabetes, venous thrombosis and cardio-
vascular disease (CVD) (2, 3). A common gene variant with a 
worldwide prevalence of 30–50 % in the patatin-like phospholipase 
domain-containing 3 gene (PNPLA3) (rs738409; C>G/I148M) in-
creases the risk of NAFLD, independently of obesity (4). It in-
creases liver fat in both humans and animal models but does not 
alter insulin sensitivity (4–6). Thus, carriers of the I148M gene 
variant are neither more obese nor do they have changes in glu-
cose or insulin concentrations or inflammation in adipose tissue 
(7, 8). The latter seems critical for the development of insulin resis-
tance in the liver (9–11). NAFLD caused by the I148M variant 
does not associate with an increased risk of diabetes or CVD (2).
Hepatocytes or sinusoidal endothelial cells in the liver are 
major sites of production of coagulation factors (12, 13). In 
NAFLD, activities of coagulation factors such as FVII (14), FVIII 
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(15), FIX (15), FXI (15), FXII (15), von Willebrand factor (VWF) 
(15, 16) and fibrinogen (15, 16) are all increased. These changes 
augment the risk of venous thrombosis and of atherothrombotic 
vascular disease (17, 18). It is, however, unknown whether the in-
crease in coagulation factors in NAFLD is due to obesity/insulin 
resistance and associates with adipose tissue inflammation or due 
to increased liver fat content per se. NAFLD caused by the 
PNPLA3 I148M variant thus provides a model in which steatosis 
can be dissociated from obesity/insulin resistance. Coagulation 
factor activities have not been studied in different types of NAFLD.
The mechanisms underlying increased activities of coagulation 
factors in NAFLD are unclear. Expression of coagulation factors in 
the human liver has not been compared between insulin resistant 
and sensitive subjects. Adipose tissue in insulin-resistant subjects 
over-expresses pro-inflammatory cytokines and chemokines, but 
shows decreased expression of anti-inflammatory adipokines (9, 
19–21). These changes impair insulin action, such as regulation of 
platelet-collagen interaction (22), and stimulate synthesis of he-
patic acute phase reactants and coagulation factors, such as fibri-
nogen, FVIII, and FXIII (23–25).
In the present study, we hypothesised that i) coagulation fac-
tor activities are higher in subjects with increased liver fat con-
tent associated with obesity/insulin resistance than in subjects 
with increased liver fat content due to PNPLA3 I148M variant, ii) 
coagulation factor production as judged from hepatic expression 
is upregulated in insulin-resistant subjects with excessive liver 
fat, and iii) adipose tissue inflammation correlates with circu-
lating coagulation factor activities. To this end, we studied, in 
representative groups of subjects, circulating coagulation factor 
activities, their expression in liver biopsies and expression of pro- 
and anti- inflammatory cytokines/chemokines in biopsies of adi-
pose tissue.
Methods
Subjects and study designs
Circulating coagulation factor activities
To examine the impact of the PNPLA3 I148M variant on plasma 
coagulation factors, we recruited 92 subjects based on the follow-
ing inclusion criteria: i) age 18 to 75 years; ii) no known acute or 
chronic disease except for obesity, hypertension, or NAFLD based 
on medical history, physical examination and standard laboratory 
tests (complete blood count, serum creatinine, thyroid-stimulating 
hormone, sodium and potassium concentrations) and electrocar-
diogram (ECG); iii) alcohol consumption less than 20 g per day in 
women and less than 30 g per day for men. None of the study sub-
jects had type 2 diabetes. The subjects were divided based on their 
PNPLA3 genotype at rs738409 into those with (PNPLA3148MM/MI) 
HOMA-IR
PNPLA3148II/PNPLA3148MM/MI
Gender (men/women)
Age (years)
BMI (kg/m2)
Waist-to-hip ratio
Smoking status (current/ex-smoker/never)
fS-insulin (mU/l)
fP-glucose (mmol/l)
HbA1c (%)
fP-triglycerides (mmol/l)
fP-HDL cholesterol (mmol/l)
fP-LDL cholesterol (mmol/l)
Leukocyte count (109/l)
P-AST (U/l)
P-ALT (U/l)
P-AST/P-ALT
Data are shown as mean ± SEM or median followed by the 25th and 75th percentile. *p<0.05, **p<0.005, ***p<0.0005. Abbreviations: ALT, alanine aminotransfe-
rase; AST, aspartate aminotransferase; BMI, body mass index; fP, fasting plasma; fS, fasting serum; HbA1c, glycosylated haemoglobin A1c; HDL, high-density lipo-
protein; HOMA-IR, homeostatic model assessment of insulin resistance; IR, insulin-resistant; IS, insulin-sensitive; LDL, low-density lipoprotein; P, plasma.
IS
(n=46)
1.0 (0.6–1.6)
27/19
22/24
40 (26–52)
28.2 ± 0.7
0.91 ± 0.01
4/0/42
4.2 (2.7–6.7)
5.4 ± 0.1
5.5 ± 0.1
1.0 (0.7–1.5)
1.5 (1.3–1.7)
2.9 (2.3–3.4)
5.5 (4.7–6.6)
25 (20–31)
22 (17–46)
1.1 ± 0.1
IR
(n=46)
3.6 (2.8–4.6) ***
27/19
23/23
43 (34–54)
33.4 ± 0.6 ***
0.99 ± 0.01 ***
6/0/40
14.1 (12.2–17.1)***
5.7 ± 0.1 *
5.7 ± 0.1 *
1.6 (1.2–2.2) ***
1.3 (1.1–1.5) **
3.1 (2.6–3.5)
6.5 (5.7–7.3) **
30 (24–45) **
39 (24–81) ***
0.8 ± 0.1 ***
PNPLA3148II
(n=54)
2.4 (1.0–3.3)
54/0
25/29
40 (27–50)
31.0 ± 0.7
0.95 ± 0.01
5/0/49
10.4 (3.9–13.4)
5.5 ± 0.1
5.6 ± 0.1
1.3 (0.9–1.9)
1.4 (1.1–1.6)
2.9 (2.3–3.4)
6.0 (5.0–7.0)
25 (21–33)
26 (19–53)
0.9 ± 0.1
PNPLA3148MM/MI
(n=38)
2.4 (1.1–3.7)
0/38
20/18
43 (31–56)
30.5 ± 0.8
0.95 ± 0.02
5/0/33
8.8 (4.5–14.3)
5.6 ± 0.1
5.6 ± 0.1
1.2 (0.9–1.7)
1.3 (1.1–1.6)
3.0 (2.5–3.5)
5.8 (5.0–7.2)
31 (25–46) *
34 (19–80)
1.0 ± 0.1
Table 1: Characteristics of the study groups.
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and without (PNPLA3148II) the I148M variant. The subjects were 
also divided based on median homeostatic model assessment of 
insulin resistance (HOMA-IR) into insulin-resistant ‘IR’ and insu-
lin-sensitive ‘IS’ groups. Clinical characteristics of these groups are 
shown in ▶ Table 1.
Since both obesity/insulin resistance and the PNPLA3 I148M 
variant are common, we also analysed coagulation factors in a 2X2 
fashion in four subgroups of subjects who had both risk factors, 
i. e. both insulin resistance and the I148M variant (‘double trouble’ 
i. e. ‘IR and PNPLA3148MM/MI’), one risk factor, i. e. either insulin re-
sistance without the gene variant (‘single trouble IR’ i. e. ‘IR and 
PNPLA3148II’) or carried the PNPLA3 I148M variant without insu-
lin resistance (’single trouble PNPLA3148MM/MI’ i. e. ‘IS and 
PNPLA3148MM/MI’), or had neither risk factor (‘IS and 
PNPLA3148II’). Clinical characteristics are shown in Suppl. Table 1 
(available online at www.thrombosis-online.com).
Gene expression of coagulation factors in the human 
liver
We determined whether changes in circulating coagulation factors 
in insulin-resistant subjects with increased liver fat content but 
lacking PNPLA3 I148M gene variant were due to changes in their 
hepatic expression. For that purpose, we recruited consecutive 
subjects undergoing bariatric surgery, in whom a liver biopsy was 
clinically indicated. Inclusion criteria were: i) age 18 to 65 years; ii) 
no known acute or chronic disease, except for obesity, hyperten-
sion, NAFLD or type 2 diabetes based on medical history, physical 
examination, standard laboratory tests (complete blood count, 
serum creatinine, thyroid-stimulating hormone, sodium and po-
tassium concentrations) and ECG; iii) daily alcohol consumption 
less than 20 g in women and less than 30 g for men; iv) no history 
of use of toxins or drugs influencing liver steatosis; and v) no use 
of any anticoagulant drugs.
The subjects were invited to a separate clinical visit one week 
prior to surgery for detailed metabolic characterisation. They 
came to the clinical research centre after an overnight fast. Body 
weight, height, body mass index (BMI), waist circumference and 
blood pressure were measured. An intravenous cannula was in-
serted in an antecubital vein for collection of blood to measure gly-
cosylated haemoglobin A1c (HbA1c), serum insulin, plasma glu-
cose, low-density lipoprotein (LDL) and high-density lipoprotein 
(HDL) cholesterol, triglyceride, aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT) concentrations, and for geno-
typing of PNPLA3 at rs738409. After basal blood sampling and an-
thropometric measurements, a 75-g oral glucose tolerance test was 
performed, during which both glucose and insulin concentrations 
at 0, 30 and 120 minutes (min) were captured. HOMA-IR was 
used as a proxy for insulin resistance (26). The Matsuda insulin 
sensitivity index was applied as another measure of insulin sensi-
tivity and was calculated from insulin and glucose concentrations 
assessed at 0, 30 and 120 min during the oral glucose tolerance test 
(27). After genotyping consecutive patients, we identified 26 sub-
jects lacking the PNPLA3 I148M gene variant (PNPLA3148II), who 
were divided into those with ‘Metabolic NAFLD’ and without 
NAFLD (‘No NAFLD’) based on % of hepatocytes with macro-
scopic steatosis in the liver biopsies (see below).
Adipose tissue inflammation
To determine whether coagulation factor activities are associated 
with pro- or anti-inflammatory cytokines or adipokines in subjects 
lacking the gene variant, i. e. in PNPLA3148II subjects, we obtained 
needle biopsies of adipose tissue from the abdominal region and 
measured coagulation factor activities in 26 such subjects (8). 
Gene expression of pro-inflammatory markers (the macrophage 
marker cluster of differentiation 68 (CD68), monocyte chemoat-
tractant protein 1 (MCP-1) and tumour necrosis factor alpha 
(TNF-α)) and of anti-inflammatory markers (ADIPOQ and Twist-
related protein-1 (TWIST1)) were measured in the adipose tissue 
biopsies, and serum MCP-1 and adiponectin concentrations in 
blood samples collected after an overnight fast (see below). The 
subjects were also characterised with respect to their clinical and 
biochemical features (Suppl. Table 3, available online at www.
thrombosis-online.com).
All studies were conducted in accordance with the Declaration 
of Helsinki. Each participant provided written informed consent 
after being explained the nature and potential risks of the study. 
The ethics committee of the Helsinki University Central Hospital 
approved the study protocol.
Methods
Liver fat (1H-MRS)
In subjects not undergoing bariatric surgery (n=92), liver fat con-
tent was determined by proton magnetic resonance spectroscopy 
(1H-MRS) and the intensity differences arising from various ac-
quisition parameters and localisation techniques were normalised 
as previously described (28). Liver fat content was expressed as a 
mass fraction (29).
Liver biopsies and histology
During bariatric surgery, wedge biopsies of the liver were obtained 
as described (30). Part of the biopsy was sent to the pathologist for 
histological assessment. The rest of the biopsy was snap-frozen in 
liquid nitrogen for subsequent isolation of RNA and analysis of 
gene expression using qPCR (see below). Liver histology was ana-
lysed by an experienced liver pathologist in a blinded fashion as 
proposed by Brunt et al. (31). NAFLD was diagnosed based on his-
tology as macroscopic steatosis in >10 % of hepatocytes (32).
Subcutaneous adipose tissue biopsies
Needle biopsies of subcutaneous abdominal adipose tissue were 
obtained under local anaesthesia with 1 % lidocain at the meta-
bolic study visit, as previously described (33). The adipose tissue 
samples were immediately frozen in liquid nitrogen and stored at 
–80 °C until analysis.
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Analysis of gene expression in adipose tissue and the 
liver
The relative mRNA concentrations of genes of interest in the liver 
and in the adipose tissue biopsies were quantified by qPCR. Total 
RNA was isolated from liver tissue by the RNeasy Mini Kit 
(Qiagen, Valencia, CA, USA) and from subcutaneous adipose tis-
sue by using the RNeasy Lipid Tissue Mini Kit (Qiagen). The RNA 
(500 ng) was reverse transcribed using the SuperScript VILO 
cDNA synthesis kit (Invitrogen, Carlsbad, CA, USA). Each sample 
was amplified in duplicate for quantification of mRNA concen-
tration of the coagulation factors (F8, F9, F11, F13A1, and FGG 
encoding FVIII, FIX, FXI, FXIII-A, and fibrinogen γ chain), pro-
inflammatory (CD68, MCP-1, TNF-α) and anti-inflammatory 
(ADIPOQ encoding adiponectin, TWIST1) markers on a Light-
Cycler® 480 (Roche Diagnostics, Rotkreuz, Switzerland) using the 
SYBR-Green kit (Roche Diagnostics). The hepatic expression of 
coagulation markers was normalised to that of the housekeeping 
gene succinate dehydrogenase complex, subunit A (SDHA). The 
adipose tissue expression of inflammation markers was normal-
ized to that of the housekeeping gene acidic ribosomal phospho-
protein 36B4 (36B4). Primer sequences are shown in Suppl. Table 
4 (available online at www.thrombosis-online.com).
Analytical procedures
Fasting plasma glucose was measured using a hexokinase method 
on an autoanalyser (Roche Diagnostics Hitachi 917, Hitachi Ltd., 
Tokyo, Japan). Fasting serum insulin concentrations were deter-
mined by time-resolved fluoroimmunoassay using Insulin Kit 
(AUTOdelfia, Wallac, Turku, Finland). HbA1c was measured by 
high-pressure liquid chromatography using a fully automated Gly-
cosylated Hemoglobin Analyser System (BioRad, Hercules, CA, 
USA). LDL and HDL cholesterol, and triglyceride concentrations 
were measured with respective enzymatic kits from Roche Diag-
nostics using an autoanalyser (Roche Diagnostics Hitachi 917, 
Hitachi Ltd.). Serum creatinine, ALT and AST concentrations 
were determined as recommended by the European Committee 
for Clinical Laboratory Standards. Serum adiponectin was 
measured using the Human Adiponectin ELISA kit from B-Bridge 
International (Cupertino, CA, USA) and serum MCP-1 using an 
ELISA kit from Quantikine, P&D Systems (Minneapolis, MN, 
USA).
Blood samples for coagulation assay were collected after an 
overnight fast from an antecubital vein into tubes containing 0.129 
mol/l citrate. Plasma was separated by centrifugation for 20 min at 
2245 g in room temperature, and frozen in aliquots that were 
stored at –70 ºC until assayed. Prothrombin time (PT, % of activity 
of normal), activated partial thromboplastin time (APTT, in sec-
onds), and activities of fibrinogen, VWF, FVII, FVIII, FIX, FXI, 
FXII and FXIII were measured using the BCS® XP coagulation 
analyser (Siemens Healthcare Diagnostics, Marburg, Germany) at 
the coagulation laboratory of Helsinki University Hospital (HUS-
LAB) as previously described (15). PT was measured with Owren 
method and the Nycotest® PT reagent (Axis-Shield, Oslo, Norway), 
APTT with the Actin® FSL reagent (Siemens Healthcare Diag-
nostics) and fibrinogen with a modification of the Clauss method 
(Multifibren® U; Siemens Healthcare Diagnostics). D-dimer was 
assessed using an immunoturbidimetric assay (Tina-quant 
D-Dimer®, Roche Diagnostics, Mannheim, Germany). VWF ris-
Figure 1: Liver fat con-
tent (A), activities of 
FVIII (B) and FIX (C), 
and APTT (D) in insulin-
sensitive (IS, n=46) ver-
sus insulin-resistant (IR, 
n=46) group, and the 
PNPLA3148II (148II, 
n=54) versus the 
PNPLA3148MM/MI 
(148MM/MI, n=38) 
group. Data are shown as 
mean ± SEM. *p<0.05 
and ***p<0.0005. APTT, 
activated partial thrombo-
plastin time; FIX, coagu-
lation factor VIII; FIX, co-
agulation factor IX; 
1H-MRS, proton magnetic 
resonance spectroscopy; P, 
plasma.
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tocetin cofactor (VWF: RCo) activity was measured using the BC® 
von Willebrand Reagent, FVII activity using Dade® Innovin® and 
Coagulation Factor VII Deficient Plasma, and FXIII activity using 
Berichrom® FXIII, all the reagents from Siemens Healthcare Diag-
nostics. For one-stage FVIII, FIX, FXI and FXII activity measure-
ments we used Pathromtin SL® and specific coagulation factor defi-
cient plasma (all from Siemens Healthcare Diagnostics). The local 
reference ranges were as follows: PT 70–130 %, APTT 23–33 s, fi-
brinogen 1.7–4.0 g/l, D-dimer <0.5 mg/l, VWF: RCo 44–183 IU/dl 
(%), FVII 76–170 %, FVIII 52–148 %, FIX 67–135 %, FXI 
60–120 %, FXII 60–150 % and FXIII 76–156 %.
Statistical analyses
Distribution of continuous variables was tested for normality using 
the D’Agostino-Pearson normality test. Data are shown as mean ± 
SEM or, for non-normally distributed data, as median followed by 
the 25th and 75th percentiles. Mean values between the groups were 
compared with the unpaired t-test and median with Mann-Whit-
ney U test, or with the one-way analysis of variance and Kruskal-
Wallis H test in the case of three or more groups. For categorical 
variables, Fisher’s exact test was used. We performed logarithmic 
transformation for non-normally distributed data when needed. 
Correlation analyses were performed using Pearson’s and Spear-
man’s correlation coefficient and partial correlation. The Grubbs’ 
test with an alpha-value 0.05 was used to identify outliers that were 
then excluded. GraphPad Prism version 6.00 for Mac (GraphPad 
Software, San Diego, CA, USA) and IBM SPSS Statistics 22.0 for 
Mac (IBM SPSS, Chicago, IL, USA) were used to perform the stat-
istical analyses. A p-value of less than 0.05 was considered statisti-
cally significant.
Results
Subject characteristics and circulating coagulation 
factor activities
The ‘IR’ and ‘IS’ groups were comparable with respect to age, 
gender and PNPLA3 genotype (▶ Table 1). Subjects in the ‘IR’ 
group had higher liver fat content (▶ Figure 1 A), fasting glucose 
and insulin, HOMA-IR, and triglyceride concentrations than the 
‘IS’ group (▶ Table 1). The PNPLA3148MM/MI group had greater 
liver fat content than the PNPLA3148II group (▶ Figure 1 A) but 
there were no differences in fasting glucose or insulin, HOMA-IR 
or triglyceride concentrations between these groups (▶ Table 1).
Coagulation activities of FVIII (▶ Figure 1 B), FIX (▶ Figure 
1 C), FXI (108 ± 2 vs 96 ± 3 %, p=0.001), FXII (111 ± 3 vs 100 ± 
4 %, p=0.02), FXIII (105 ± 3 vs 96 ± 3 %, p=0.05), VWF: RCo (124 
± 7 vs 99 ± 7 %, p=0.01), the concentration of fibrinogen (4.2 ± 0.2 
vs 3.6 ± 0.2 g/l, p=0.01) and PT (124 ± 3 vs 114 ± 3 %, p=0.01) were 
all significantly higher and APTT (▶ Figure 1 D) shorter in the ‘IR’ 
than the ‘IS’ group. Activities of FVII (118 (110–132) vs 114 % 
(100–129), p=0.18) and D-dimer concentrations (0.15 (0.05–0.30) 
vs 0.08 mg/l (0.05–0.20), p=0.20) did not differ between ‘IR’ and 
‘IS’ groups.
In contrast, all coagulation variables were comparable between 
the PNPLA3148MM/MI and PNPLA3148II groups: FVII (117 (97–128) 
vs 117 % (106–130), p=0.55), FVIII (▶ Figure 1 B), FIX (▶ Figure 
1 C), FXI (102 ± 3 vs 103 ± 2 %, p=0.86), FXII (105 ± 4 vs 106 ± 
3 %, p=0.80), FXIII (104 ± 4 vs 99 ± 3, p=0.29), fibrinogen (3.9 ± 
0.2 vs 4.0 ± 0.2 g/l, p=0.52), VWF: RCo (114 ± 7 vs 110 ± 7 IU/dl, 
p=0.69), PT (121 ± 4 vs 117 ± 2 %, p=0.43), APTT (▶ Figure 1 D) 
and D-dimer (0.10 (0.05–0.30) vs 0.10 mg/l (0.05–0.20), p=0.99), 
despite the liver fat distinction.
The degree of insulin resistance assessed by HOMA-IR corre-
lated positively with activities of FVII, FVIII, FIX, FXI, FXII, 
FXIII, VWF: RCo, fibrinogen and PT, and inversely with APTT. 
The relationships between HOMA-IR and activities of FVII, FVIII, 
FIX, FXI, FXII, VWF: RCo, PT and APTT remained significant 
after adjustment for age, gender, BMI and PNPLA3 genotype. Cor-
relation coefficients and p-values are shown in Suppl. Table 5 
(available online at www.thrombosis-online.com).
Characteristics of the subjects divided in a 2×2 fashion based 
on both the PNPLA3 genotype and insulin sensitivity are shown in 
HOMA-IR
Matsuda ISI
PNPLA3148II/PNPLA3148MM/MI
Gender (men/women)
Age (years)
BMI (kg/m2)
Waist circumference (cm)
Waist-to-hip ratio
Smoking status (current/ex-smoker/never)
fP-glucose (mmol/l)
fS-insulin (mU/l)
fS-C-peptide (nmol/l)
HbA1c (%)
fP-triglycerides (mmol/l)
fP-HDL cholesterol (mmol/l)
Liver fat content (histology, %)
P-AST (U/l)
P-ALT (U/l)
Data are shown as mean ± SEM or median followed by the 25th and 75th per-
centile. *p<0.05, **p<0.005, ***p<0.0005. Abbreviations: ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; 
fP, fasting plasma; fS, fasting serum; HbA1c, glycosylated haemoglobin A1c; 
HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of 
insulin resistance; ISI, insulin sensitivity index; LDL, low-density lipoprotein; 
NAFLD, non-alcoholic fatty liver disease; P, plasma.
No NAFLD
(n=13)
1.7 (1.2–3.2)
79 (50–145)
13/0
4/9
44 ± 1
45.7 ± 1.7
130 ± 4
0.99 ± 0.04
3/5/5
5.2 (4.7–5.9)
7.9 (5.5–12.5)
0.87 ± 0.09
5.7 ± 0.2
1.1 (0.8–2.1)
1.1 ± 0.1
3.1 ± 1.2
31 (25–39)
34 ± 3
Metabolic 
NAFLD
(n=13)
4.6 (2.9–6.9) **
35 (24–59) *
13/0
6/7
44 ± 2
45.7 ± 0.9
137 ± 4
1.02 ± 0.03
3/4/6
5.8 (5.3–6.2)
19.0 (12.1–26.6) *
1.41 ± 0.12 **
6.2 ± 0.2
1.5 (1.2–2.0)
1.0 ± 0.1
45.8 ± 6.8 ***
35 (28–41)
52 ± 6 *
Table 2: Characteristics of subjects undergoing liver biopsies.
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Suppl. Table 1 (available online at www.thrombosis-online.com). 
Activities of FVIII, FIX, FXI, fibrinogen and VWF: RCo were in-
creased and APTT was shortened in IR as compared to IS subjects 
without the PNPLA3 gene variant (‘IR and PNPLA3148II’ vs ‘IS and 
PNPLA3148II’, Suppl. Table 2, available online at www.thrombosis-
online.com). The PNPLA3 genotype did not influence the coagu-
lation variables in either IS or IR subjects (Suppl. Table 2, available 
online at www.thrombosis-online.com).
Expression of F8, F9, FGG, F11 and F13A in the human 
liver
Characteristics of the subjects lacking the PNPLA3 I148M gene 
variant who underwent a liver biopsy (n=26) are shown in ▶ Table 
2. The subjects with ‘Metabolic NAFLD’ as compared to those 
without NAFLD had higher fasting serum insulin, HOMA-IR and 
plasma ALT, and lower Matsuda insulin sensitivity index (▶ Table 
2). The groups were equally obese and did not differ in age or 
gender.
The gene expression of F8, F9 and FGG were higher in the 
‘Metabolic NAFLD’ than in the ‘No NAFLD’ group (▶ Figure 2). 
Expression of F11 (1.1 ± 0.1 vs 1.0 ± 0.1, p=0.11) and F13A1 (1.2 ± 
0.1 vs 1.0 ± 0.1, p=0.28) did not differ between the ‘Metabolic 
NAFLD’ and ‘No NAFLD’ groups.
Relationship between coagulation factors activities 
and expression of pro- and anti-inflammatory 
markers in adipose tissue and in serum in subjects 
lacking the PNPLA3 I148M gene variant (PNPLA3148II)
Characteristics of the subjects lacking the PNPLA3 I148M gene 
variant who underwent an adipose tissue biopsy are shown in 
Suppl. Table 3 (available online at www.thrombosis-online.com). 
Gene expression of the macrophage marker CD68 in adipose tis-
sue correlated positively with PT % (▶ Figure 3 A), FIX (▶ Figure 
3 B), FXI (r=0.44, p<0.05) and VWF: RCo (r=0.40, p<0.05) activ-
ities, fibrinogen (▶ Figure 3 C), and D-dimer (r=0.59, p<0.01). 
Gene expression of MCP-1 correlated with FVIII (r=0.53, p<0.01), 
VWF: RCo (r=0.59, p<0.01) and D-dimer (r=0.60, p<0.01), and 
TNF-α with FIX (r=0.45, p<0.05) and FXI (r=0.47, p<0.05). Adi-
pose tissue expression of the anti-inflammatory marker ADIPOQ 
correlated inversely with FIX (r=-0.39, p<0.05) and fibrinogen 
(r=-0.41, p<0.05), and that of TWIST1 with the vitamin K–de-
pendent coagulation factors, PT % (r=-0.57, p<0.01) and FIX 
(r=-0.57, p<0.01) and with D-dimer (r=-0.48, p<0.01). Serum 
MCP-1 correlated positively with VWF: RCo (r=0.47, p=0.02) and 
serum adiponectin inversely with functional fibrinogen in plasma 
(r=-0.43, p=0.04).
Discussion
In the present study, increased clotting activity characterised insu-
lin-resistant subjects with increased liver fat compared to insulin-
sensitive subjects. Subjects with the PNPLA3 I148M gene variant 
had a similar increase in liver fat as the insulin-resistant subjects in 
the absence of insulin resistance. Increases in liver fat were also ac-
companied by increases in serum AST and ALT. All coagulation 
variables were comparable between carriers and non-carriers of 
Figure 2: Expression of F8, F9 and FGG relative to the housekeeping 
gene in the liver of subjects in ‘No NAFLD’ (white columns, n=13) 
and ‘Metabolic NAFLD’ (grey columns, n=13) groups. Data are shown 
as mean ± SEM. *p<0.05 and **p<0.005. F8, coagulation factor VIII; F9, co-
agulation factor IX; FGG, fibrinogen γ chain; NAFLD, non-alcoholic fatty liver 
disease.
Figure 3: Relationships 
(Pearson’s correlation 
coefficient) between PT 
(A), activity of FIX (B) 
and fibrinogen (C), and 
adipose tissue ex-
pression of CD68 in 26 
non-bariatric subjects 
without the PNPLA3 
I148M gene variant. PT, 
prothrombin time; FIX, co-
agulation factor IX; P, plas-
ma.
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I148M variant, despite distinct amounts of fat in the liver. Subjects 
with ‘Metabolic NAFLD’, i. e. those who were lacking the I148M 
variant but had insulin resistance and fatty liver, had clearly up-
regulated hepatic expression of F8, F9 and FGG compared to 
equally obese subjects without NAFLD. Thus, obesity does not ex-
plain increased coagulation factor expression in insulin-resistant 
subjects with NAFLD. In subjects lacking the PNPLA3 I148M gene 
variant, adipose tissue pro-inflammatory markers correlated posi-
tively and anti-inflammatory markers inversely with activities of 
FVIII, FIX, FXI, VWF: RCo and functional fibrinogen. These data 
demonstrate that insulin resistance rather than liver fat influences 
circulating coagulation factors and their susceptibility for acti-
vation. We suggest that adipose tissue inflammation and insulin 
resistance regulates FVIII, FIX and fibrinogen activities at the level 
of gene expression in the liver.
Increased FVIII activity is associated with CVD (34), insulin re-
sistance (35) and risk of venous thromboembolism (36). In the 
present study, activities of FVIII and its binding protein VWF were 
elevated in insulin-resistant subjects with increased liver fat but 
not in carriers of the PNPLA3 I148M variant with a compatible 
liver fat content. This shows that increased liver fat per se does not 
explain increased FVIII or VWF: RCo activities in humans. We 
also found, to our knowledge for the first time in human liver 
samples, that gene expression of F8, which encodes for FVIII, was 
upregulated in the insulin-resistant subjects with increased liver fat 
compared to insulin-sensitive with normal liver fat (▶ Figure 2). 
FVIII is an acute phase protein, which is transcriptionally respon-
sive to NFκB activation by pro-inflammatory cytokines (37). The 
relationship between adipose tissue MCP-1 expression and FVIII 
activity supports the idea that adipose tissue inflammation, sys-
temic insulin resistance and hepatic acute-phase protein produc-
tion are closely interrelated (9–11, 38).
FIX and FXI activities were increased in subjects with high liver 
fat content and insulin resistance, but not in PNPLA3 I148M vari-
ant carriers with high liver fat without insulin resistance. FIX (39) 
and FXI (40) are produced almost exclusively by the liver but their 
expression has not been compared between insulin-resistant and 
sensitive groups. We found the expression of F9 but not F11 to be 
upregulated in insulin-resistant subjects with ‘Metabolic NAFLD’ 
as compared to insulin-sensitive subjects without NAFLD. Simi-
larly to FVIII, FIX and FXI activities were closely correlated with 
the markers of inflammation and adipokines in adipose tissue. 
Previous studies have reported circulating interleukin 6 and high-
sensitive C-reactive protein, markers of low-grade inflammation 
in insulin-resistant subjects (41), to correlate with the activities of 
FVIII, FIX, FXI, fibrinogen and VWF, and shortened prothrombin 
time (42, 43). These data show that increased FIX and XI activities 
reflect obesity/insulin resistance rather than liver fat content per 
se, and that changes in FIX activity could reflect regulation of gene 
expression in the liver. However, regulation of FIX activity is com-
plex (44, 45), and cannot be determined in a cross-sectional in vivo 
study.
The liver is the main source of the inhibitory subunit B of FXIII 
(46), while the active subunit A is expressed in liver, macrophages, 
monocytes and platelets (47, 48). This together with the present 
data showing elevated FXIII activity but unchanged hepatic ex-
pression of F13A1 in insulin-resistant subjects implies that FXIII 
activity is regulated via mechanisms other than those involving 
changes in hepatic F13A1 expression.
The finding of increased fibrinogen concentration in insulin-
resistant subjects with increased liver fat is keeping with previous 
reports in obese subjects with NAFLD compared to less obese sub-
jects without NAFLD (16). We extend previous data by showing 
that expression of fibrinogen, especially its γ chain, is upregulated 
in the liver of insulin-resistant subjects with ‘Metabolic NAFLD’ 
lacking the PNPLA3 gene variant. Consistent with the idea that the 
increase in fibrinogen gene expression could be a downstream 
event, reflecting inflammation in extra-hepatic tissues (23), adi-
pose tissue expression of the macrophage marker CD68 correlated 
positively and adiponectin inversely with functional fibrinogen in 
plasma.
The extrinsic coagulation pathway including prothrombin, 
FVII and FX (49) is triggered by tissue factor, which is closely as-
sociated with atherosclerotic plaques (50). PT measures the activ-
ity of this pathway, and APTT assesses the activity of the intrinsic 
coagulation pathway consisting of prothrombin, FV, VIII, IX, X, 
XI and XII, and fibrinogen (12). In the present study, subjects with 
increased liver fat and insulin resistance had shortened PT (i. e. % 
of normal was increased) and APTT, implying that the changes in 
individual coagulation factors indeed translated into a signifi-
cantly enhanced clotting activity.
Coagulation factor activities and insulin sensitivity were un-
changed between subjects with and without PNPLA3 I148M vari-
ant, despite distinct liver fat contents. This finding accords with 
multiple studies showing that the PNPLA3 I148M gene variant 
predisposes to liver disease but not insulin resistance or risks of 
type 2 diabetes or CVD (2).
What is known about this topic?
• In non-alcoholic fatty liver disease (NAFLD), activities of coagu-
lation factors are elevated. These changes may increase the risk of 
venous thrombosis and of atherothrombotic vascular disease.
• It is unknown whether the increment of coagulation factor activ-
ities in NAFLD is due to obesity/insulin resistance and associated 
adipose tissue inflammation or due to increased liver fat content 
per se.
What does this paper add?
• Clotting activity characterised insulin-resistant subjects with in-
creased liver fat but not those with increased liver fat due to the 
PNPLA3 I148M variant. This indicates that obesity/insulin resis-
tance rather than an increase in liver fat per se is associated with 
a procoagulant plasma profile.
• Hepatic gene expression of coagulation factors FVIII, FIX and fi-
brinogen is upregulated in insulin-resistant subjects with NAFLD.
• The degree of insulin resistance and adipose tissue inflammation 
correlate with activities of coagulation factors.
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Taken together these data show that circulating coagulation 
factor activities are upregulated in subjects who have both an in-
creased liver fat content and insulin resistance (‘Metabolic 
NAFLD’) but not in subjects who merely have an increased liver 
fat content due to the I148M PNPLA3 gene variant (‘PNPLA3 
NAFLD’). Therefore, the patient who has ‘Metabolic NAFLD’ is 
likely to be at greater risk of thrombosis while the patient with 
‘PNPLA3 NAFLD’ is not at such risk.
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